Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

SYRE

Spyre Therapeutics Inc.

Oct 15 • 04:00PM ET

31.48

Dollar change +0.82
Percentage change 2.67	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA BMY PFE LLY NVS

| Held by: VTI IWM XBI VXF IWN SCHA VTWO DWAS VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-15.45	Insider Own	10.86%	Shs Outstand	50.92M	Perf Week	12.91%
Market Cap	1.60B	Forward P/E	-	EPS next Y	-3.89	Insider Trans	-0.33%	Shs Float	45.39M	Perf Month	8.70%
Income	-185.98M	PEG	-	EPS next Q	-0.82	Inst Own	92.41%	Short Float	19.04%	Perf Quarter	0.25%
Sales	0.00M	P/S	-	EPS this Y	92.00%	Inst Trans	108.76%	Short Ratio	17.88	Perf Half Y	-13.21%
Book/sh	4.30	P/B	7.31	EPS next Y	0.94%	ROA	-54.73%	Short Interest	8.64M	Perf Year	142.53%
Cash/sh	8.37	P/C	3.76	EPS next 5Y	-	ROE	-222.71%	52W Range	8.43 - 47.97	Perf YTD	46.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.60%	ROI	-49.68%	52W High	-34.38%	Beta	2.93
Dividend TTM	-	Quick Ratio	19.70	Sales past 5Y	-49.91%	Gross Margin	39.53%	52W Low	273.43%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	19.70	EPS Y/Y TTM	79.05%	Oper. Margin	0.00%	RSI (14)	62.19	Volatility	6.47% 6.05%
Employees	30	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.10	Target Price	45.75
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	98.49%	Payout	-	Rel Volume	1.30	Prev Close	30.66
Sales Surprise	-100.00%	EPS Surprise	9.45%	Sales Q/Q	-100.00%	Earnings	Aug 07 AMC	Avg Volume	483.45K	Price	31.48
SMA20	9.34%	SMA50	13.52%	SMA200	4.76%	Trades		Volume	626,138	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Loading…
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
08:00AM	Loading…
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)
Dec-07-23 06:20PM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire)
Nov-28-23 08:00AM	Spyre Therapeutics to Present at Upcoming Investor Conference (PR Newswire) +20.73%
Nov-27-23 08:30AM	Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD (PR Newswire) +8.79%
Nov-22-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) +6.26%
06:26PM	Loading…
Nov-09-23 06:26PM	Aeglea: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) -5.39%
Oct-30-23 08:00PM	Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences (PR Newswire) +9.57%
Oct-02-23 06:02PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire)
Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)
Sep-05-23 07:00AM	Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones (PR Newswire)
Aug-11-23 07:07AM	Aeglea: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-27-23 07:00AM	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma (PR Newswire)
Jun-23-23 04:30PM	Aeglea BioTherapeutics Announces Grant of Inducement Awards (PR Newswire) -12.30% -5.30%
10:31AM	Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics (Zacks)
Jun-22-23 10:59AM	Aeglea BioTherapeutics Stock Surges Over 400% Today - What's Going On (Benzinga) +328.67%
08:17AM	Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics (PR Newswire)
May-13-23 08:03AM	Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:15AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Aeglea: Q1 Earnings Snapshot (AP Finance)
07:01AM	Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 09:44AM	Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails (Zacks) -7.37%
Apr-12-23 07:00AM	Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives (PR Newswire) -26.21%
Mar-17-23 05:30PM	Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.35%
Mar-02-23 10:15AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates (PR Newswire)
Feb-12-23 07:40AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 months (Simply Wall St.)
Jan-06-23 07:01AM	Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency (PR Newswire)
Jan-02-23 07:29AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Dec-14-22 12:00PM	Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-02-22 04:05PM	Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +18.17% -5.90%
Nov-30-22 10:38AM	Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease (Benzinga) -65.98%
07:01AM	Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer (PR Newswire)
Nov-15-22 04:25PM	Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer (PR Newswire) -5.88%
Nov-03-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.56%
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +6.02%
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-19-22 04:05PM	Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment (PR Newswire)
Oct-17-22 11:57AM	NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce (Zacks)
Oct-04-22 11:05AM	FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients (Benzinga)
07:01AM	Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program (PR Newswire)
Aug-29-22 04:05PM	Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 (PR Newswire) +16.74% -13.51%
Aug-27-22 09:18AM	Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares (Simply Wall St.)
Aug-25-22 11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-24-22 12:40PM	Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus (Benzinga) -19.87%
08:01AM	Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring (PR Newswire)
Aug-22-22 12:28PM	Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment (Zacks) -17.15%
Aug-20-22 10:49AM	Even after rising 85% this past week, Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders are still down 88% over the past three years (Simply Wall St.)
Aug-19-22 06:26AM	Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today? (Benzinga) +80.23%
Aug-18-22 04:05PM	Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Aug-04-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.41%
07:01AM	Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Jul-24-22 10:41AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks) -5.22%
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.86%
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks)
Jun-09-22 09:56AM	Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is not what insiders may have expected (Simply Wall St.)
Jun-03-22 10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks) -14.51%
Jun-02-22 03:26PM	Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug (Zacks) -51.33%
03:20PM	Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals (Zacks)
12:09PM	Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy (Zacks)
11:24AM	Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug (Zacks)
08:59AM	Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -5.06%
02:22PM	FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug (Zacks)
May-31-22 11:26AM	GSK to Boost Vaccine Portfolio With Affinivax Acquisition (Zacks)
May-26-22 11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe (Zacks)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burrows Scott L	Chief Financial Officer	Sep 03 '24	Sale	28.17	18,531	522,074	116,422	Sep 05 04:04 PM
Fairmount Funds Management LLC	Director	Apr 25 '24	Option Exercise	0.00	3,639,680	0	4,018,101	Apr 25 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYRE

Spyre Therapeutics Inc.

Upgrade your FINVIZ experience